- Home
- AMZE vs GLTO Comparison
AMZE vs GLTO Comparison
Compare AMZE & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMZE
- GLTO
- Stock Information
- Founded
- AMZE 2019
- GLTO 2011
- Country
- AMZE United States
- GLTO Denmark
- Employees
- AMZE N/A
- GLTO N/A
- Industry
- AMZE Beverages (Production/Distribution)
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- AMZE Consumer Staples
- GLTO Health Care
- Exchange
- AMZE Nasdaq
- GLTO Nasdaq
- Market Cap
- AMZE 5.2M
- GLTO 4.4M
- IPO Year
- AMZE 2021
- GLTO 2020
- Fundamental
- Price
- AMZE $10.00
- GLTO $3.35
- Analyst Decision
- AMZE
- GLTO Buy
- Analyst Count
- AMZE 0
- GLTO 1
- Target Price
- AMZE N/A
- GLTO $10.00
- AVG Volume (30 Days)
- AMZE 71.2K
- GLTO 18.8K
- Earning Date
- AMZE 08-13-2025
- GLTO 08-11-2025
- Dividend Yield
- AMZE N/A
- GLTO N/A
- EPS Growth
- AMZE N/A
- GLTO N/A
- EPS
- AMZE N/A
- GLTO N/A
- Revenue
- AMZE $254,711.00
- GLTO N/A
- Revenue This Year
- AMZE N/A
- GLTO N/A
- Revenue Next Year
- AMZE N/A
- GLTO N/A
- P/E Ratio
- AMZE N/A
- GLTO N/A
- Revenue Growth
- AMZE N/A
- GLTO N/A
- 52 Week Low
- AMZE $5.78
- GLTO $2.01
- 52 Week High
- AMZE $28.72
- GLTO $16.07
- Technical
- Relative Strength Index (RSI)
- AMZE N/A
- GLTO 65.19
- Support Level
- AMZE N/A
- GLTO $3.19
- Resistance Level
- AMZE N/A
- GLTO $3.63
- Average True Range (ATR)
- AMZE 0.00
- GLTO 0.24
- MACD
- AMZE 0.00
- GLTO 0.01
- Stochastic Oscillator
- AMZE 0.00
- GLTO 79.37
About AMZE Amaze Holdings Inc. Common Stock
Amaze Holdings Inc is engaged in producer of low carb, low calorie, premium wines in the United States. The company offers bold, crisp, and creamy wines that embody health, warmth, and a deeper connection to wellness and an active lifestyle. The company currently sell seven proprietary varietals: Cabernet Sauvignon, Pinot Noir, Chardonnay, Sauvignon Blanc, Rose, Sparkling Rose, and a limited Reserve Napa Cabernet Sauvignon.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.